# MAGEB6

## Overview
MAGEB6 is a gene that encodes the protein MAGE family member B6, which is part of the melanoma-associated antigen (MAGE) family. This family is characterized by its expression in a variety of tumors and restricted expression in normal tissues, primarily the testis, which classifies it as a cancer/testis antigen (Simpson2005Cancertestis). The MAGEB6 protein is implicated in several cellular processes, including transcription regulation and cellular metabolism, although its precise biological functions remain to be fully elucidated. Located on the X chromosome, MAGEB6 is part of a gene cluster associated with sex-reversal phenotypes and has been linked to various cancers, making it a potential target for cancer immunotherapy (Lucas2000MAGEB5). The gene's tumor-specific expression and involvement in oncogenic pathways highlight its potential as a biomarker and therapeutic target in oncology (Conconi2016Unexpected).

## Clinical Significance
MAGEB6, a member of the MAGE gene family, is primarily expressed in tumors and not in normal tissues, except for the testis, making it a potential target for cancer immunotherapy. Its expression has been associated with various cancers, including seminomas, melanoma, esophageal carcinoma, and non-small-cell lung carcinoma (Lucas2000MAGEB5). The gene is located on the X chromosome and is part of a cluster of MAGEB genes that have been linked to sex-reversal phenotypes (Simpson2005Cancertestis).

Alterations in the expression of MAGEB6 have been observed in colorectal carcinoma, where copy number gains involving the MAGEB6 gene have been frequently reported (Conconi2016Unexpected). These genomic alterations suggest a role for MAGEB6 in tumorigenesis, potentially through mechanisms involving the regulation of biological processes such as transcription, gene expression, and cellular metabolism (Conconi2016Unexpected).

The tumor-specific expression pattern of MAGEB6, along with its involvement in cancer-related pathways, underscores its clinical significance as a biomarker for certain cancers and as a candidate for targeted cancer therapies (Lucas2000MAGEB5).


## References


[1. (Simpson2005Cancertestis) Andrew J. G. Simpson, Otavia L. Caballero, Achim Jungbluth, Yao-Tseng Chen, and Lloyd J. Old. Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer, 5(8):615–625, July 2005. URL: http://dx.doi.org/10.1038/nrc1669, doi:10.1038/nrc1669. This article has 1257 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrc1669)

[2. (Lucas2000MAGEB5) Sophie Lucas, Etienne De Plaen, and Thierry Boon. Mage-b5, mage-b6, mage-c2, andmage-c3: four new members of themage family with tumor-specific expression. International Journal of Cancer, 87(1):55–60, 2000. URL: http://dx.doi.org/10.1002/1097-0215(20000701)87:1<55::aid-ijc8>3.0.co;2-j, doi:10.1002/1097-0215(20000701)87:1<55::aid-ijc8>3.0.co;2-j. This article has 91 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/1097-0215(20000701)87:1)

[3. (Conconi2016Unexpected) Donatella Conconi, Serena Redaelli, Giorgio Bovo, Biagio Eugenio Leone, Emanuela Filippi, Luciana Ambrosiani, Maria Grazia Cerrito, Emanuela Grassilli, Roberto Giovannoni, Leda Dalprà, and Marialuisa Lavitrano. Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients. Tumor Biology, 37(10):13831–13842, August 2016. URL: http://dx.doi.org/10.1007/s13277-016-5181-0, doi:10.1007/s13277-016-5181-0. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13277-016-5181-0)